ASND Ascendis Pharma A/S - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
ASND Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$235.39
Analyst Target
$272.95
+16.0%
Upside
52W High
$238.84
52W Low
$118.03
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a weak fundamental health with a Piotroski F-Score of just 1/9, indicating significant financial distress risks. Despite this, the company exhibits exceptional revenue growth of 269.4% YoY and strong gross margins of 86.8%, reflecting robust commercial execution and pricing power. However, negative profitability metrics, a deeply negative Price/Book ratio, and inconsistent earnings delivery—evidenced by a -231.9% average earnings surprise over the last four quarters—undermine long-term sustainability. While analysts maintain a strong_buy consensus with a target price of $272.95, the stock trades at a premium Forward P/E of 53.40, demanding flawless future execution.
Key Strengths
Exceptional year-over-year revenue growth of 269.4%, significantly outpacing sector average of 60.85%
High gross margin of 86.80%, indicating strong pricing power and low cost of goods sold
Analyst consensus is strong_buy with a 15-analyst average target price of $272.95, implying ~16% upside
Operating margin positive at 5.15% despite overall net losses, suggesting improving operational efficiency
Strong recent price performance: +84.6% over 1 year and +92.3% over 3 years
Key Risks
Critically low Piotroski F-Score of 1/9, signaling severe financial weakness and poor earnings quality
Negative ROA (-7.69%) and negative profit margin (-36.03%), indicating ongoing unprofitability
Poor earnings predictability: only 1 out of last 4 quarters beat estimates, with an average surprise of -231.9%
Very weak liquidity profile: Quick Ratio of 0.70 suggests potential short-term solvency concerns
Extremely high valuation: Forward P/E of 53.40 and Price/Sales of 22.24, exceeding sector averages
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare ASND against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning ASND from our newsroom.
Newest → oldest
No matching news yet.